Bjerke, Maria

Engelborghs, Sebastiaan

Goossens, Joery

Somers, Charisse

Abstract: Although the core cerebrospinal fluid Alzheimers disease (AD) biomarkers amyloid-\u3b2 (A\u3b2142) and tau show a high diagnostic accuracy, there are still limitations due to overlap in the biomarker levels with other neurodegenerative and dementia disorders. During A\u3b2142 production and clearance in the brain, several other A\u3b2 peptides and amyloid precursor protein fragments are formed that could potentially serve as biomarkers for this ongoing disease process. Therefore, this review will present the current status of the findings for amyloid precursor protein and A\u3b2 peptide isoforms in AD and clinically related disorders. In conclusion, adding new A\u3b2 isoforms to the AD biomarker panel may improve early differential diagnostic accuracy and increase the cerebrospinal fluid biomarker concordance with AD neuropathological findings in the brain

Selecting A f isoforms for an Alzheimers disease cerebrospinal fluid biomarker panel

Abstract

Similar works

Full text

Available Versions

Institutional Repository Universiteit Antwerpen